MagnetisMM-7

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab VS Lenalidomide in Participants with Newly Diagnosed Multiple Myeloma Who Have Had an Autologous Stem Cell Transplant

What's the purpose of the trial?

The goal of this clinical trial is to compare the safety and effectiveness of Elranatamab versus Lenalidomide in participants with newly diagnosed multiple myeloma who have recently undergone autologous stem cell transplant. 

Trial status

Accepting patients

Phase
Phase 3
Enrollment
760
Last Updated
2 months ago
Am I Eligible

Participating Centers

There are 14 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Elranatamab is a B-Cell Maturation Antigen (BCMA) CD-3 bispecific antibody being tested in multiple myeloma
  • Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Arm B: Lenalidomide

Accepting patients

Arm C: Elranatamab Maintenance Therapy

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.